Disclaimer for the US market

The products and information provided on this website are intended for healthcare professionals. These products are not for sale or distribution in the United States and statements made regarding these products have not been evaluated by the U.S. Food and Drug Administration (FDA). The efficacy of these products has not been confirmed by FDA-approved research and these products are therefore not intended to diagnose, treat, cure or prevent any disease. All information presented here is for general information purposes only and not meant as a substitute for or alternative to advice from healthcare practitioners. The Federal Food, Drug and Cosmetic Act requires this notice.

Neither the Company nor its representatives is providing any medical advice, and none should be inferred, from any ideas, suggestions, testimonials or other information set forth on this website or in other Company materials or provided over the phone, in the mail, in product packaging, or in email correspondence. This website may contain links to third-party websites. The Company provides these links as a convenience only and does not endorse any of these sites. The Company is not responsible for the content of, and does not make any representations regarding the materials on, such linked third-party websites. If you decide to access or rely on information at linked third-party website, you do so at our own risk. Our terms and conditions, including disclaimers, are more fully set forth in our Terms of Use, Privacy Policy and Terms of Online Sales.

CARL. News

Dear Sir or Madam,

We are delighted to present you today the first issue of CARL News!

The new online newsletter format of Resuscitec GmbH will inform you from now on about all top news concerning trade fair appearances, training dates and events around the CARL System.

Over the past twelve years, our company has developed from a start-up to a medium-sized enterprise. Established in 2010 as a spin-off of the Freiburg University Hospital, we have set ourselves the goal of making a fundamental contribution to saving lives more efficiently with our products – thereby shifting the limits of resuscitation.

In the meantime, we have already passed important milestones on the way to this goal. The CARL System got for instance CE-certified in 2020 and in the same year a Post Market Clinical Follow-up Study (PMCF) started at four European centers, which has delivered promising results until today. As a result, we successfully launched CARL in the European market at the beginning of this year – and are now looking forward to continuing the success story of a medical technology vision, which became reality through the contribution of expert scientists and engineers.

Join us on our journey and learn first-hand how CARL will hopefully save more and more lives today and in the future!

Enjoy the reading and best wishes,

Jörg Ronde                         Christoph Benk

CFO                                       CTO

Press contact

Resuscitec GmbH
Engesserstraße 4a
D-79108 Freiburg
press@resuscitec.de

We always use the masculine form in our texts when referring to persons so as not to impair the flow of reading. However, the masculine gender explicitly represents all genders on our website.

Disclaimer

You are receiving the CARL. News mailing based on your relationship with our company. We process your data on the basis of our legitimate interest for the purpose of addressing you personally and sending you our CARL. News mailing. Responsible for the data processing is Resuscitec GmbH. For further information on data protection, please refer to our privacy policy. You can informally object to the processing of your personal data for the dispatch of the CARL. News mailing at any time. Please use the unsubscribe link below to do so.

Note of use

For copyright reasons, the articles may not be passed on to third parties either in print or digital. They are for personal use only. Building up a database with digitizied articles is not allowed.